Unicycive Therapeutics Inc
UNCY4.150USD
+0.130+3.23%
終値 09/29, 16:00（ET）15分遅れの株価
58.56M時価総額
損失額直近12ヶ月PER
詳細情報 Unicycive Therapeutics Inc 企業名
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
Unicycive Therapeutics Incの企業情報
企業コードUNCY
会社名Unicycive Therapeutics Inc
上場日Jun 17, 2021
最高経営責任者「CEO」Dr. Shalabh Gupta, M.D.
従業員数22
証券種類Ordinary Share
決算期末Jun 17
本社所在地4300 El Camino Real, Suite 210
都市LOS ALTOS
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号94022
電話番号16503840642
ウェブサイトhttps://unicycive.com/
企業コードUNCY
上場日Jun 17, 2021
最高経営責任者「CEO」Dr. Shalabh Gupta, M.D.
Unicycive Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Aug 19
更新時刻: Tue, Aug 19
株主統計
種類
株主統計
株主統計
比率
Vivo Capital, LLC
6.44%
Octagon Capital Advisors LP
5.66%
Nantahala Capital Management, LLC
5.32%
Great Point Partners, LLC
4.51%
The Vanguard Group, Inc.
3.43%
他の
74.64%
株主統計
株主統計
比率
Vivo Capital, LLC
6.44%
Octagon Capital Advisors LP
5.66%
Nantahala Capital Management, LLC
5.32%
Great Point Partners, LLC
4.51%
The Vanguard Group, Inc.
3.43%
他の
74.64%
種類
株主統計
比率
Hedge Fund
17.84%
Venture Capital
9.12%
Individual Investor
3.56%
Investment Advisor
3.44%
Investment Advisor/Hedge Fund
0.53%
Research Firm
0.13%
他の
65.38%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
2023Q2
42
9.36M
61.47%
-512.55K
2023Q1
38
9.94M
65.95%
+1.31M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Vivo Capital, LLC
1.14M
8.9%
+140.00K
+14.04%
Mar 31, 2025
Octagon Capital Advisors LP
1.00M
7.83%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
939.20K
7.36%
-100.00K
-9.62%
Mar 31, 2025
Great Point Partners, LLC
1.10M
8.6%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
121.24K
0.95%
+7.42K
+6.52%
Mar 31, 2025
Gupta (Shalabh K)
597.25K
4.68%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
507.89K
3.98%
--
--
Mar 31, 2025
Rosalind Advisors, Inc.
242.49K
1.9%
+242.49K
--
Apr 30, 2025
Armistice Capital LLC
97.60K
0.76%
--
--
Dec 31, 2023
Acuta Capital Partners, LLC
235.29K
1.84%
+4.99K
+2.17%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Tue, Sep 2
更新時刻: Tue, Sep 2
銘柄名
比率
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
